FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.
What happened
FDA reviewed the company's website at https://www.refills.com in December 2025 and found it offering compounded drug products, including semaglutide, a diabetes and weight-loss medicine. The site's pictured labels name "Refills Health," which suggests the company compounded the drugs when FDA says it did not. The site also called the products "clinically proven" and said they contain "the same active ingredient found in certain FDA approved treatments," even though compounded drugs are not FDA-approved.
What FDA found
Website labels show "Refills Health" on the product label, which tells buyers the company made the drug when it did not, making the labeling false or misleading (misbranded).
FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)Advertising claims for a compounded drug that are false or misleading also make the drug misbranded.
FDCA § 502(bb) [21 U.S.C. § 352(bb)]Calling the products "clinically proven" implies FDA approval or a safety and effectiveness review that never happened.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Saying the products contain "the same active ingredient found in certain FDA approved treatments" suggests the compounded drugs are FDA-approved when they are not.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]These compounded products are "new drugs" not generally recognized as safe and effective, so they must meet the conditions in section 503A or 503B to be exempt from approval requirements.
FDCA §§ 201(p), 503A, 503B [21 U.S.C. §§ 321(p), 353a, 353b]Shipping misbranded drugs, and receiving or delivering them in interstate commerce, is a prohibited act.
FDCA §§ 301(a), 301(c) [21 U.S.C. §§ 331(a), 331(c)]
What FDA wants
Within 15 working days the company must send CDER's Office of Compounding Quality and Compliance a written response describing the steps taken to fix the violations and prevent them from recurring. FDA specifically asks the company to identify who actually makes the compounded products, supply sample labeling, and fix or remove the misleading website claims.
Who should pay attention
- telehealth platforms selling compounded semaglutide and other GLP-1 drugs
- compounding pharmacies whose products are resold or marketed under another company's name
- marketing and affiliate teams writing drug claims for online pharmacy sites
This is a summary. Read the original letter on fda.gov.